RITUXIMAB; HYALURONIDASE (HUMAN RECOMBINANT) | B761064 | GENENTECH INC
Regulatory Exclusivities
| Type | Expiry | Status | Source |
|---|---|---|---|
| 12-Year BPCIA | Jun. 22, 2029 | Active | Computed |
| 7-Year Orphan | Jun. 22, 2024 | Expired | Purple Book |
Purple Book Patents
No listed patents in Purple Book.
Estimated Patent LOE
Based on latest discovered patent 12421324(formulation) · relevance 70/100
Estimate based on AI-discovered patents. No patents are officially listed in the Purple Book for this product.
Top 50 of 171 AI-discovered patents by relevance.
No patent or exclusivity listings for this strength.